Phase 1 trial results show Covaxin has tolerable safety, enhanced immunity: Lancet study
Friday, 22 January 2021 India's first indigenous vaccine against COVID-19, Covaxin, showed enhanced immune response without any serious side effects in the participants enrolled for the phase 1 trials, according to the results published in The Lancet Infectious Disease journal. Developed by Bharat Biotech in collaboration with the ICMR and the National Institute of Virology (NIV), Pune, the vaccine has been granted emergency use authorisation in clinical trial mode' by the Indian government.
More than a dozen slum residents in Bhopal, India, say they thought they were being vaccinated for Covid-19. They say they later discovered from local activists that some of them hadn’t been given an approved vaccine and had unwittingly taken part in a Phase 3 clinical trial for India’s homegrown vaccine, Covaxin. CNN’s Vedika Sud reports.
Indian Council of Medical Research DG, Balram Bhargava announced that the Covaxin is successful in tackling UK strain. He further informed that UK variant strain is now present in 70 countries and 164 cases have been identified in India. "UK variant strain is now present in 70 countries and we've identified 164 cases of it in India. We were able to find the first case of the UK variant on 22nd-23rd December. In a week's time, we were able to collect blood from these patients and culture the strain. We found that the neutralisation of UK strain was equivalent to Indian strains circulating in India. It's a very reassuring news that UK variant can be tackled by this vaccine," informed ICMR DG during a press briefing on January 28.
On February 27, total COVID-19 tally of India reached to 1,10,79,979. The country reported 16,488 new COVID-19 cases in last 24 hours and active cases stand at 1,59,590. With new 12,771 discharges, total number is at 1,07,63,451. 113 deaths were reported in last 24 hours, taking cumulative toll to 1,56,938. 1,42,42,547 beneficiaries have been vaccinated for COVID-19 across India.
A UNESCO World Heritage site in Poland is being used to help people recover from COVID-19, with patients going deep underground in the Wieliczka salt mine to a therapeutic centre dealing with respiratory illness. Libby Hogan reports.
Director General of ICMR, Dr. Balram Bhargava, said that indigenously developed Bharat Biotech vaccine might have some advantages over other vaccines on the new strain of COVID that was found in UK. He said, "NIV scientists have successfully isolated the new virus strain and this will be tested against different vaccines. We hope potentially Bharat Biotech vaccine will have some advantages over other vaccines on this new strain because it is a whole virus." "New virus variant which is now more than 60% infective and creating havoc in the UK is worrisome. There are 29 patients in India with the same variant for which we should be cautious. We have been able to isolate the new virus very soon," added Dr. Balram Bhargava.
On February 26, total COVID-19 tally of India reached to 1,10,63,491. The country reported 16,577 new COVID-19 cases in last 24 hours and active cases stand at 1,55,986 . With new 12,179 discharges, total number reached to 1,07,50,680. 120 deaths were reported in last 24 hours, taking cumulative toll to 1,56,825. 1,34,72,643 beneficiaries have been vaccinated for COVID-19 across India. According to ICMR, total number of samples tested up to Feb 25 is 21,46,61,465 including 8,31,807 samples tested yesterday.
On February 25, the total COVID-19 tally of India reached to 1,10,46,914. The country reported 16,738 new COVID-19 cases in last 24 hours and active cases stands at 1,51,708. With new 11,799 discharges, total number reached to 1,07,38,501. 138 deaths were reported in last 24 hours, taking cumulative toll to 1,56,705. 1,26,71,163 beneficiaries have been vaccinated for COVID-19 across India. According to Indian Council of Medical Research (ICMR), 21,38,29,658 samples tested up to 24th February.
The Health and Family Welfare Minister of Tamil Nadu, Dr C Vijayabaskar took Bharat Biotech's Covaxin shot. He took the shot in Chennai on morning of January 22. Dr C Vijayabaskar requested all to get vaccinated and safeguard themselves from COVID-19 pandemic. Billed as the world's largest vaccination programme, covering the entire length and breadth of the country, the drive aims to first inoculate millions of its healthcare and frontline workers and reach an estimated 3 crore people by the end of its first phase. The mega COVID-19 vaccination drive began in India on January 16 (Saturday).
Karnataka Association of Resident Doctors (KARD) has demanded the government to let people choose which COVID-19 vaccine, between Pune-based Serum Institute of India's Covishield and Hyderabad-based Bharat Biotech's Covaxin, they want to take. "Government of India has approved Covishield and Covaxin vaccines. We have all the reports for Covishield. But, Covaxin is still in phase-III trials, where the trial is being done on healthcare workers. We condemn this...Healthcare workers should be given a choice of vaccine," said Dr Dayanand Sagar. GoI rolled out COVID-19 vaccine jab from January 16.
NITI Aayog Member (Health) Dr VK Paul said that phase 3 trial of Pfizer, Moderna is still going on but the benefits are overwhelming compared to risk. "World has decided to move forward, take benefit..
Congress MP Manish Tewari raised objection on the rollout of Covaxin. Manish Tewari said that government should either not roll out Covaxin till its efficacy and reliability is completely established..